Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. on December 23, 2015. The filing discloses the entry into a material definitive agreement for a registered direct offering of securities to institutional investors. The company is incorporated in Nevada and operates from Richmond, California.

Key Financial Metrics and Transaction Details

  • Aggregate Proceeds: $15,000,000.
  • Securities Issued: 15,000 shares of Series A Convertible Preferred Stock and warrants to purchase 14,851,486 shares of Common Stock.
  • Purchase Price: $1,000 per unit (one Preferred Share plus related Warrants).
  • Preferred Stock Conversion: Convertible into Common Stock at a price of $1.01 per share, subject to adjustments.
  • Warrant Terms: Exercise price of $1.25 per share; five-year term; immediately exercisable.
  • Transaction Costs: Placement agent fees equal to 6.2% of gross proceeds.
  • Liquidity Impact: The filing does not provide current cash balance, debt levels, or operating margins; it focuses solely on the capital raise.

Material Changes and Transaction Structure

The primary material change is the execution of a Securities Purchase Agreement to raise $15 million. The transaction involves the creation of a new class of equity, Series A Convertible Preferred Stock, which is perpetual with no required dividend or liquidation preference. The offering includes significant anti-dilution protections for investors, including price-based adjustments until the company completes qualified financings totaling at least $10 million in aggregate gross proceeds. Additionally, the company has agreed to ownership limitations, restricting holders from exercising warrants to exceed 4.99% of outstanding Common Stock (increasable to 9.99% with notice).

Outlook, Risks, and Management Commentary

  • Closing Date: The financing is expected to close on or about December 28, 2015, subject to customary conditions.
  • Regulatory Status: Securities are being sold pursuant to an effective shelf registration statement (Form S-3) declared effective on July 9, 2015.
  • Call Provision: The Company retains the right to call for cancellation of unexercised warrants for consideration equal to their Black Scholes value, subject to limitations.
  • Fundamental Transactions: In the event of a fundamental transaction, warrant holders may receive cash equal to the Black Scholes value of the unexercised portion or the securities they would have received upon exercise.
  • Risks: The filing does not explicitly list new operational risks but notes standard dilution adjustments and ownership caps.

Investor Verification Checklist

  • Verify the actual closing date of the financing and confirmation of fund receipt.
  • Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution adjustment formulas.
  • Confirm the identity of the institutional investors (Purchasers) and their post-transaction ownership percentages.
  • Assess the impact of the 6.2% placement fee on net proceeds available for operations.
  • Monitor future filings for the exercise of warrants and conversion of Preferred Stock into Common Stock.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.